HK Stock Market Move | Shanghai Fosun Pharmaceutical (02196) rose over 5% in early trading after its holding subsidiary sold approximately 6.00% equity of Gland Pharma for 27.996 billion Indian Rupees.

Shanghai Fosun Pharmaceutical (02196) rose over 5% in early trading; as of the time of publication, it was up 4.63% at HKD 16.95, with a transaction volume of HKD 31.6777 million. In news, Shanghai Fosun Pharmaceutical announced that on September 4, 2026, Indian time, its subsidiary Shanghai Fosun Pharmaceutical Singapore will sell a total of 9.897 million shares of Gland Pharma (approximately 6.00% of Gland Pharma's total shares as of September 3, 2026) through bulk trading and centralized bidding. The total transaction value (before deducting transaction commissions and taxes) is INR 27.996 billion (approximately USD 294 million1), with an average price (before deducting transaction commissions and taxes) of around INR 2828.78 per share, which is a discount of approximately 2.72% compared to the closing price of the previous trading day (INR 2907.90). The transfer of shares from this transaction is expected to take place on September 7, 2026, Indian time. Following the completion of this transaction, the group will still hold approximately 45.76% of Gland Pharma's equity (down from approximately 51.76% before this transaction), making it the controlling shareholder, while Gland Pharma will remain a subsidiary within the groups consolidated financial statements. The proceeds from this transaction will mainly be used for the group's R&D investments, share buybacks, repayment of interest-bearing debts, and other purposes. The proceeds from this sale will enhance the group's net assets; since this transaction involves the transfer of part of the equity of a controlling subsidiary, the proceeds will not be included in the group's income statement as investment income. The actual financial impact will be subject to the audit results.